Innovative Therapies in the Treatment of PTSD

Bionomics is innovating the way we treat PTSD and other trauma-related disorders through the advancement of its late-stage, lead candidate, BNC210. This primary asset is a novel, orally-administered, first-in-class, negative allosteric modulator (NAM) of the α7 nicotinic acetylcholine receptor, and has been granted Fast Track designation by the US FDA. The company is comprised of a deep bench of experienced scientists, and has partnered with atai’s EmpathBio to explore combinations with MDMA therapy for PTSD.